Identification of Approval Conditions for Orphan Drugs for Neurological Disorders by the Japanese Regulatory Agency

Expert Opinion on Orphan Drugs - United Kingdom
doi 10.1080/21678707.2018.1496013
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Pivotal Studies of Orphan Drugs Approved for Neurological Diseases

Annals of Neurology
Neurology
2009English

Psy130 - The Relationship Between Disease Type and Conditional or Exceptional Approval by Ema for Orphan Drugs in 2017

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Php96 - Time Efficiency in the Regulatory Decision-Making Process of Orphan Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Ketogenic Diets for Adult Neurological Disorders

Neurotherapeutics
NeurologyPharmacology
2018English

Economic Impact of the End of the Market Exclusivity for Orphan Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Safety Related Label Changes for New Drugs After Approval in the US Through Expedited Regulatory Pathways: Retrospective Cohort Study

British Medical Journal
Medicine
2017English

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2011English

Hta Studies on Orphan Drugs by Rebratsxmembers

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Psy185 - Alternative Methodologies Implemented by Hta Agencies for Orphan Drugs: A Scoping Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy